Skip to main content
. Author manuscript; available in PMC: 2020 May 21.
Published in final edited form as: Curr Top Med Chem. 2009;9(15):1479–1492. doi: 10.2174/156802609789895728

Table 1.

Hsp90 Inhibitors in Clinical Development

Inhibitor Structure Route Phase Company
Tanespimycin (17-AAG) graphic file with name nihms-1586953-t0001.jpg i.v. III BMS Kosan
Retaspimycin hydrochloride (IPI-504) graphic file with name nihms-1586953-t0002.jpg i.v. II Infinity
IPI-493 graphic file with name nihms-1586953-t0003.jpg oral I Infinity
SNX-5422 mesylate graphic file with name nihms-1586953-t0004.jpg oral I Pfizer Serenex, Inc.
AUY922 graphic file with name nihms-1586953-t0005.jpg i.v. I/II Novartis
BIIB021 CNF-2024 graphic file with name nihms-1586953-t0006.jpg oral II Biogen Idec
BIIB028 Small molecule* i.v. I Biogen Idec
STA-9090 Resorcinol derivative* i.v. I/II Synta
KW-2478 Small molecule* i.v. I Kyowa Hakko Kirin
AT13387 Small molecule* oral, i.v. I Astex Therapeutics
XL888 Small molecule* oral I Exelixis
HSP990 Small molecule* oral I Novartis
MPC-3100 Small molecule* oral I Myriad Pharmaceuticals
ABI-010 Nanoparticle albumin-bound 17-AAG i.v. I Abraxis Bioscience
*

The structures are not reported.